EUVIMEDEUVIMED entdecken
Crossref

Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer: A Retrospective Study

Yoh-Ichiro Iwasa, Kentaro Hori, Yoh Yokota, Ryosuke Kitoh, Shintaro Yamazaki, Takuya Okubo, Yutaka Takumi

Anticancer Research · 2026

DOI: 10.21873/anticanres.18010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Yoh-Ichiro Iwasa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan iwasa@shinshu-u.ac.jp. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Head and Neck Neoplasms, Neck Dissection, Nivolumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: T-cell priming within tumor-draining lymph nodes (TDLNs) is essential for optimal immune checkpoint inhibitor (ICI) activity. Because neck dissection (ND) removes cervical lymph nodes that may function as TDLNs in head and neck cancer (HNC), its impact on subsequent ICI efficacy remains clinically relevant. This study investigated whether prior ND influences treatment outcomes with nivolumab in recurrent or metastatic HNC. PATIENTS AND METHODS: Fifty-four patients with recurrent or metastatic HNC treated with nivolumab between 2017 and 2025 were retrospectively analyzed. Patients were stratified into locoregional disease (LRD; n=41) and distant metastasis (DM; n=13) cohorts. Within each cohort, outcomes were compared between patients with and without prior ND. RESULTS: In the LRD cohort (n=41), the median progression-free survival was 2.3 vs. 4.0 months (p=0.089) and median overall survival was 9.8 vs. 18.8 months (p=0.044) for the ND and non-ND groups, respectively. In the DM cohort (n=13), outcomes were unaffected by ND. Multivariate analysis showed a non-significant trend toward worse outcomes in the ND group. CONCLUSION: Prior ND was associated with inferior survival in LRD but not in DM-only disease, suggesting that an ND-related loss of TDLN function reduces ICI efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsHead and Neck NeoplasmsNeck DissectionNivolumabHumansFemaleRetrospective StudiesMaleMiddle AgedAgedNeoplasm Recurrence, LocalTreatment OutcomeAdultAged, 80 and overLymphatic Metastasis

Stichwörter der Autor:innen

Nivolumabhead and neck cancerimmune checkpoint inhibitorneck dissectionprogrammed cell death-1 (PD-1)

Substanzen

Immune Checkpoint InhibitorsNivolumab

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan iwasa@shinshu-u.ac.jp.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Zitieren

APA

Iwasa, Y. I., Hori, K., Yokota, Y., Kitoh, R., Yamazaki, S., Okubo, T., & Takumi, Y. (2026). Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer: A Retrospective Study. Anticancer Research. https://doi.org/10.21873/anticanres.18010

Vancouver

Iwasa YI, Hori K, Yokota Y, Kitoh R, Yamazaki S, Okubo T, et al. Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer: A Retrospective Study. Anticancer Research. 2026. doi:10.21873/anticanres.18010

BibTeX
@article{Iwasa2026,
  author = {Iwasa, Yoh-Ichiro and Hori, Kentaro and Yokota, Yoh and Kitoh, Ryosuke and Yamazaki, Shintaro and Okubo, Takuya and Takumi, Yutaka},
  title = {Neck Dissection and Immune Checkpoint Inhibitor Efficacy in Head and Neck Cancer: A Retrospective Study},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18010}
}
Kostenlos starten →